Often linked to tumours arising from the chromosomal instability pathway, representing 80–85% of CRC cases, KRAS mutations have been associated with increased activity of ERK signalling, thereby promoting transcription of Elk-1 and c-Myc (Bos et al, 1987; Jass, 2007). This evidence concerns the gene KRAS and colorectal carcinoma.